胸腺法新在感染和重症相关领域临床应用专家共识  

Expert consensus on the clinical application of thymosin alpha 1 in infectious diseases and critical care medicine

作　　者：国家感染性疾病临床医学研究中心 国家传染病医学中心 李兰娟[2] 黄建荣[2] National Clinical Research Center for Infectious Diseases;National Medical Center for Infectious Diseases;Li Lanjuan;Huang Jianrong(不详;Department of Infectious Diseases,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]不详 [2]浙江大学医学院附属第一医院感染病科,杭州310003

出　　处：《中华临床感染病杂志》2024年第4期252-262,共11页Chinese Journal of Clinical Infectious Diseases

基　　金：国家重点研发计划(2022YFC2304500);国家科技重大专项(2017ZX10203201)。

摘　　要：随着免疫治疗被越来越多的临床医师关注和应用,免疫调节治疗在感染和重症领域的应用也越来越广泛。作为免疫调节治疗的经典药物,胸腺法新在相关治疗领域已积累了较多临床证据。国家感染性疾病临床医学研究中心和国家传染病医学中心等组织多学科专家,参照国内外最新研究成果,参考基于证据质量以外的其他因素(经济学、患者偏好和价值观、利弊权衡、可及性、公平性及可接受性等)对循证医学证据的等级和推荐意见强度进行评估,形成了10条应用胸腺法新治疗肝病、病毒感染、细菌感染,以及重症感染等疾病的推荐意见,从而希望增进临床医师对胸腺法新的了解,提高临床应用的规范性。As immunotherapy gains increasing attention and clinical application,the immune modulation therapy has been widely used in treatment of infectious and critical diseases.And clinical evidence has been accumulated for application of thymosin alpha 1,a classical immune modulator,in related domains.National Clinical Research Center for Infectious Diseases,National Medical Center for Infectious Diseases and other institutions invited multidisciplinary experts to develop this Expert consensus on clinical application of thymosin alpha 1 in infectious diseases and critical care medicine.Based on the latest domestic and international research findings and considering relevant factors,including economics,patient preferences and values,trade-offs,accessibility,fairness and acceptability,the consensus assesses the quality levels of current evidence and forms 10 recommendations on the application of thymosin alpha 1 in treatment of liver diseases,viral infections,bacterial infections,and critical illnesses.This consensus aims to enhance understanding of thymosin alpha 1 and improving its standardized application for clinicians.

关 键 词：胸腺法新 感染性疾病 危重症 临床应用 共识 

分 类 号：R979.5[医药卫生—药品]